Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006632003
Thu, 17.09.2020
MorphoSys AG
MorphoSys and Incyte to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas
Analyst and investor conference call and webcast scheduled for Tuesday, September 29, 2020 at 9:00 a.m. EDT / 3:00 p.m. CEST
PLANEGG/MUNICH and WILMINGTON, Del., USA - September 17, 2020 - MorphoSys AG ( [ … ]
Thu, 17.09.2020
MorphoSys AG
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
Phase 1 Clinical Study Expected to Start in Q4 2020
PLANEGG/MUNICH Germany and SHANGHAI, China, September 17, 2020 - MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab (Nasdaq: IMAB) today join [ … ]
Tue, 18.08.2020
MorphoSys AG
National Comprehensive Cancer Network(R) Adds Monjuvi(R) (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
PLANEGG/MUNICH, Germany and WILMINGTON, Del. - August 18, 2020 - MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (Nasdaq:INCY) today announced that Monjuvi(R) (taf [ … ]
Wed, 05.08.2020
MorphoSys AG
Planegg/Munich, Germany, August 5, 2020
MorphoSys Reports Second Quarter and First Half
2020 Results
Conference call and webcast (in English) to be held on August 6, 2020 at 2:00pm CEST (1:00pm BST/8:00am EDT)
MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) reports results for the second quarter and first half of [ … ]
Sat, 01.08.2020
MorphoSys AG
FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)- First FDA approval of a second-line treatment for adult patients with relapsed or refractory DLBCL, helping fill a high unmet medical need
- FDA granted Monjuvi Fast Tra [ … ]
Sat, 01.08.2020
MorphoSys AG
Ad hoc release according to article 17 para. 1 MAR
Planegg/Munich, Germany, August 1, 2020
Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; N [ … ]
Thu, 30.07.2020
MorphoSys AG
Planegg/Munich, Germany, July 30, 2020
Invitation to MorphoSys' Second Quarter and First Half 2020 Results Conference Call on August 6, 2020
MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will publish its results for the second quarter and first half of 2020 on August 5, 2020 at 10:00pm CEST (9:00pm BST; 4:00pm ED [ … ]